However, efficacy of anti-EGFR seemed limited in this cohort for non-V600E BRAF-mutant and RAS wild-type patients, and the predictive impact of these rare mutations remains unknown so far.13BRAF-mt CRC used throughout this article will thus refer exclusively to the V600E mutation. This evidence concerns the gene BRAF and colorectal carcinoma.